During her talk, Ms. Bhattacharya will provide a corporate update on Nanoscope's recent and upcoming progress across pipeline programs. She will specifically cover Nanoscope's lead asset MCO-010, ...

As a result, the majority of recombinant AAV (rAAV) gene therapy programs focus on these areas to address existing medical challenges, leveraging AAV’s tropism to enhance treatment efficacy and ...

Focused specifically on examining gene therapy immunogenicity, this event will enable you to learn how to evaluate and overcome pre-existing immunity to AAV vectors, understand how immune ...

INS1201 represents the first application of Insmed’s targeted adeno-associated virus (AAV) delivery platform ... which may overcome the immunogenicity barriers associated with existing viral ...

AAV is a virus with low immunogenicity and a simple structure, used for delivering therapeutic genes into the body, developing treatments for congenital genetic disorders. The company has also ...

INS1201 represents the first application of Insmed’s targeted AAV delivery platform in DMD ... which may overcome the immunogenicity barriers associated with existing viral vector-based treatments.

Laboratory of Thermodynamics, Department of Biochemical and Chemical Engineering, TU Dortmund University, Emil-Figge-Street 70, Dortmund 44227, Germany ...

Safety, immunogenicity, pharmacokinetics ... Prevalence of serum IgG and neutralizing factors against adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population ...